Literature DB >> 7047984

Effects of the disaccharidase inhibitor acarbose on meal and intravenous glucose tolerance in normal man.

G Dimitriadis, P Tessari, V Go, J Gerich.   

Abstract

To determine whether the effects of the disaccharidase inhibitor Acarbose on glucose tolerance could be solely explained via an action on intestinal nutrient absorption, the effects of this agent and placebo (100 mg p.o.) on intravenous and postprandial glucose tolerance were compared in six normal subjects. Acarbose significantly diminished plasma glucose, insulin, and gastrointestinal inhibitory polypeptide responses following meal ingestion without affecting plasma glucagon and pancreatic polypeptide responses, but had no effect on plasma glucose and insulin responses following intravenous injection of glucose. These results suggest that the acute effects of Acarbose on glucose tolerance can be explained on the basis of its ability to alter intestinal nutrient absorption.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047984     DOI: 10.1016/0026-0495(82)90084-1

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Long-term treatment with acarbose for the treatment of reactive hypoglycemia.

Authors:  A G Ozgen; F Hamulu; F Bayraktar; S Cetínkalp; C Yilmaz; M Túzún; T Kabalak
Journal:  Eat Weight Disord       Date:  1998-09       Impact factor: 4.652

2.  Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus.

Authors:  G Dimitriadis; S Raptis; A Raptis; E Hatziagelaki; A Mitrakou; P Halvatsiotis; S Ladas; I Hillebrand
Journal:  Klin Wochenschr       Date:  1986-05-02

Review 3.  Management of insulin-dependent diabetes mellitus.

Authors:  D M Nathan
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 4.  Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  S P Clissold; C Edwards
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

Review 5.  A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.

Authors:  F Santeusanio; P Compagnucci
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

6.  The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs.

Authors:  Sanjay Kalra; Yashdeep Gupta
Journal:  Diabetes Ther       Date:  2016-03-10       Impact factor: 2.945

7.  Diabetes medications as potential calorie restriction mimetics-a focus on the alpha-glucosidase inhibitor acarbose.

Authors:  Daniel L Smith; Rachael M Orlandella; David B Allison; Lyse A Norian
Journal:  Geroscience       Date:  2020-10-02       Impact factor: 7.713

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.